Q2 FY2026 EarningsQ2 FY26 missed consensus on top-line and bottom-line metrics: revenue of $0.09M vs. $0.12M expected, and GAAP EPS of -$0.38 vs. -$0.375 expected. The revenue miss was primarily driven by a 100% YoY decline in partnership revenue following the termination of the Terumo agreement. However, R&D momentum remains strong with the BACKBEAT trial on track for completion by Q3 2026, and the company maintain a solid liquidity position of $110M to fund operations into Q4 2027.
Financial report interval: 2026.03.30 - 2026.06.30
Overview: Orchestra BioMed(OBIO) the Revenue is 88 K (-89.47%), Miss estimate;the EBIT is -22.36 M (-15.67%), Beat estimate;the EPS is -0.38 (+24%), Miss estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
RevenueMiss expectations
0.00B89.47%
0.00B85.86%
-0.00B3.61%
EBITExceed expectations
-0.02B15.67%
-0.02B23.52%
+0.00B7.85%
EPSMiss expectations
-0.3824.00%
-0.37525.00%
-0.00501.00%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf